A Guide to Evaluating Head and Neck Lymph Nodes in Cancer: What Imaging Reveals and Why It Matters

Table of Contents

• Key Points
• Background: Why Lymph Node Evaluation Matters
• Lymph Node Anatomy: How These Structures Work
• Lymphatic Drainage Patterns in the Head and Neck
• Size Criteria: Why Size Alone Is Not Enough
• Imaging Findings in Metastatic Lymph Nodes
• PET Imaging: Seeing What CT and MRI Cannot
• Extranodal Extension: When Cancer Breaks Through
• Grading Systems for Extranodal Extension
• How Extranodal Extension Affects Cancer Staging
• Lymphoproliferative Disorders: A Special Challenge
• Limitations of Current Imaging Approaches
• Clinical Implications for Patients
• Recommendations and Practical Approach
• Frequently Asked Questions
• Source Information

Key Points

• Lymph nodes are often the first place head and neck cancer spreads, so accurate imaging evaluation is essential for staging, prognosis, and treatment planning.
• Size alone is unreliable: up to 50% of metastatic nodes measure less than 0.5 cm, so shape, texture, and metabolic activity must also be assessed.
• PET imaging adds critical metabolic information and can identify metastatic nodes that appear normal on CT or MRI, potentially changing staging and treatment.
• Extranodal extension (cancer breaking through the lymph node capsule) is a negative prognostic factor that can increase cancer stage and may require more intensive treatment.
• After surgery or radiation, enlarged lymph nodes may be due to altered drainage rather than recurrent cancer; PET imaging helps distinguish these possibilities.

Background: Why Lymph Node Evaluation Matters

Lymph nodes are small, bean-shaped organs that filter lymph fluid and help the immune system fight infection. They also are often the first place cancer spreads when a tumor begins in the head or neck. Because of this, accurate identification and characterization of lymph nodes is essential for cancer staging, prognosis, and treatment planning.

The authors of this review article explain that mischaracterizing a lymph node can lead to incorrect diagnoses and suboptimal treatment. They underscore the need for precise imaging evaluation and standardized reporting across all medical centers.

Modern imaging tools such as contrast-enhanced CT (computed tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography) have greatly improved the ability to assess lymph node abnormalities. However, challenges remain in distinguishing between benign (non-cancerous) and malignant (cancerous) nodes. This article reviews cervical lymph node anatomy, drainage patterns, imaging features of abnormal nodes, and key reporting considerations, with particular emphasis on extranodal extension.

Lymph Node Anatomy: How These Structures Work

Lymph nodes are small, kidney-shaped structures that play a crucial role in the immune system. They filter lymph fluid, trap foreign particles, and facilitate the activation of lymphocytes (immune cells).

Anatomically, lymph nodes consist of multiple lymphoid lobules surrounded by lymph-filled sinuses enclosed by a capsule. The lobules contain three main compartments: the cortex, paracortex, and medulla. Each compartment houses specific B and T lymphocytes.

On CT and MRI, normal lymph nodes appear as well-defined, homogeneous structures with a central fatty hilum (the area where blood vessels and lymphatic vessels enter and exit). On ultrasound, normal lymph nodes appear as hypoechoic (darker) structures with a central echogenic (bright) hilum.

The arterial supply to lymph nodes typically comes from small branches of nearby arteries. Venous drainage follows a similar pattern, ensuring sufficient circulation and immune surveillance.

When disease affects a lymph node, the imaging appearance changes. Abnormal lymph nodes may enlarge, change shape, or increase in number. Importantly, changes in shape and appearance may be seen before size abnormalities occur. These early changes include:

• Inhomogeneity (uneven texture within the node)
• Heterogeneous enhancement (uneven uptake of contrast dye)
• Loss of the normal fatty hilum

The authors note that familiarity with normal variations in lymph node appearance with age is necessary to avoid false positives. In general, larger lymph nodes are present in younger individuals. With increasing age, nodes decrease in number and become smaller due to fibrosis, lipomatosis (fat accumulation), and a decrease in postcapillary vessels. This ultimately leads to decreased lymphoid tissue.

Lymphatic Drainage Patterns in the Head and Neck

Understanding drainage patterns of head and neck lymph nodes is crucial for predicting how cancer spreads. Conversely, knowing where abnormal lymph nodes appear can help identify the location of a primary (original) tumor.

Cervical lymph nodes and lymphatic drainage in the neck can be organized based on anatomic location or seven stations/levels. Each station receives lymphatic fluid from distinct anatomical areas. All stations ultimately drain into the jugular trunk and then to the lymphatic duct on the right side and the thoracic duct on the left side.

Knowledge of drainage patterns directs the search for cancer. For example, in the setting of oropharyngeal carcinoma (cancer of the throat), level II and III nodal stations must be carefully examined for metastatic nodal disease.

Some lymph nodes are not assigned to nodal stations I to VII. These include the parotid and retropharyngeal lymph nodes, which are often overlooked on imaging. The parotid space, suboccipital, and retro- or subauricular regions are the main nodal basins for cutaneous carcinomas (skin cancers) of the scalp. Nasopharyngeal carcinoma often metastasizes to retropharyngeal lymph nodes.

Significant changes in lymphatic drainage can occur following surgery and radiation therapy. Therefore, post-treatment imaging must be interpreted in the context of the given therapy. Studies have shown that surgical lymph node dissection can cause significant disruptions in normal lymphatic flow, including vessel rupture and development of collateral lymphatic vessels.

In head and neck cancer, treatment often results in lymphatic dermal backflow, potentially leading to lymphedema (swelling) and enlarged lymph nodes. Lymphedema is often transient but can persist in some patients. In the post-treatment setting, an enlarging lymph node may be located at an atypical and unexpected location. Doctors must differentiate between normal enlargement due to altered lymphatic drainage and recurrent nodal metastatic disease. PET imaging is helpful in distinguishing a new metastatic lymph node in this setting, and biopsy may be necessary for definitive characterization.

Size Criteria: Why Size Alone Is Not Enough

The American Joint Commission on Cancer (AJCC) guidelines on staging head and neck cancers considers three categories when evaluating metastatic cervical lymph nodes. These categories are nodal size in greatest dimension, laterality of a lymph node (ipsilateral versus contralateral), and presence of extranodal extension. A radiology report must mention these findings.

However, significant variability exists in the medical literature regarding size criteria to classify a node as abnormal. This leads to confusion among radiologists, referring clinicians, and patients.

There is a balance between sensitivity (finding all cancers) and specificity (avoiding false positives). Classifications with a larger size cutoff have lower sensitivity for disease detection, missing small but pathologic nodes, but higher specificity with low false positive results.

Some publications classify pathologically enlarged lymph nodes as:

• Greater than 1.5 cm in longitudinal diameter for level I and II nodes
• Greater than 0.8 cm for retropharyngeal nodes
• Greater than 1 cm for other cervical nodal chains

Others favor using the short axis and consider nodes abnormal if:

• Level I and II nodes exceed 1.1 cm
• Retropharyngeal nodes exceed 0.5 cm
• Other cervical nodes exceed 1 cm

The lack of consensus in the literature leads to significant variability in radiology reports. This may cause confusion in staging and treatment response assessment.

The probability of metastasis increases with increasing abnormal nodal size. In cases of primary head and neck malignancy, the authors report long-axis measurement to ensure concordance with AJCC staging and to replicate what the examining clinician reports.

In general, lymph nodes larger than 6 cm designate N3 disease, while nodes between 3 and 6 cm designate N2 disease for HPV-negative oropharyngeal carcinoma, hypopharyngeal and laryngeal carcinomas. Nodal masses greater than 6 cm are usually conglomerate nodes with extranodal extension of disease.

Although size is a helpful factor in identifying metastasis, it is estimated that up to 50% of metastatic nodes measure less than 0.5 cm. This underscores the importance of morphologic and metabolic changes and avoiding overreliance on size criteria alone.

Reactive nodes present additional difficulty, as they may be considered abnormal by size criteria but be a normal physiologic response. For this reason, most patients at the authors' institution with a newly diagnosed head and neck primary malignancy undergo a contrast-enhanced CT and PET imaging. Exceptions include those with T1 disease in the setting of vocal cord or oral cavity carcinoma because the risk for nodal disease and distant metastasis is extremely low.

Imaging Findings in Metastatic Lymph Nodes

Anatomic nodal characteristics are obtained with CT, MRI, and ultrasound, while metabolic characteristics are obtained with PET imaging. Key morphologic changes suggesting metastatic disease include:

• Loss of reniform (kidney-like) shape
• Loss of fatty hilum
• Necrotic and cystic changes

Necrosis within a lymph node appears as internal debris. This may be due to severe infection, ischemia (lack of blood flow), or rapid tumor growth. A cystic lymph node has a well-defined fluid-filled cavity, which may be a manifestation of necrosis.

HPV-associated oropharyngeal carcinoma (HPV-OPSCC) results in degradation of keratin and cellular debris within the metastatic lymph node deposits. As a result, blockage of lymphatic flow causes necrosis and, ultimately, a cystic appearance. Necrosis and cystic changes have the highest specificity for metastatic disease.

On ultrasound, nodal disease manifests as a more rounded shape and/or loss of the echogenic fatty hilum. In some cases, tumor infiltration may result in cortical thickening.

On CT, a heterogeneous node with areas of central low attenuation is consistent with necrosis. A well-defined fluid-filled cavity with peripheral enhancement is consistent with cystic change. Both are considered abnormal regardless of size.

On MRI, nodal necrosis and cystic change show high T2 and low T1 signal with heterogeneous post-contrast enhancement.

Necrosis and cystic change in nodes are commonly seen in the setting of HPV-OPSCC and papillary thyroid carcinoma. They can also be seen in cases of nasopharyngeal carcinoma and lymphoma. A mixed cystic and calcified lymph node favors papillary thyroid carcinoma.

In an adult patient, a cystic lymph node should not be mistaken for a branchial cleft cyst or abscess. Necrotic or cystic lymph nodes at level II should be considered metastasis until proven otherwise.

PET Imaging: Seeing What CT and MRI Cannot

PET imaging plays an important and complementary role in evaluating head and neck malignancy. It allows for accurate staging of nodal and distant metastatic disease.

The workhorse tracer for malignancy assessment is F-18 Fluorodeoxyglucose (FDG). This allows for semi-quantitative assessment of tumor compared to normal background uptake.

Since size criteria alone have low sensitivity for identifying abnormal nodes, correlating anatomic CT findings with metabolic PET imaging allows for improved identification of metastatic nodes that maintain normal size. These nodes otherwise may have been missed.

An SUVmax threshold of approximately 4.05 has been reported for malignant cervical nodes. This threshold has a sensitivity of 92% and a specificity of 88%.

Although the negative predictive value of FDG PET-CT for cervical nodal disease is high at 92%, the corresponding false negative rate is 29%. Positive predictive values reportedly range from 13% to 94%. These numbers warrant caution in the era of increasing non-surgical treatment and clinical staging.

Necrotic and cystic lymph nodes, although clearly abnormal, may not have corresponding hypermetabolic activity. Uptake, if any, is more likely to be at the periphery and absent in the central necrotic and cystic portion.

Extranodal Extension: When Cancer Breaks Through

Extranodal extension (ENE) is often discussed during tumor boards because its presence serves as a negative prognostic factor. It is associated with a high risk for disease progression and metastasis.

Definitive identification of ENE on imaging, referred to as iENE (imaging-detected extranodal extension), may be used to guide treatment. This potentially decreases toxicity and cost of trimodal therapy, which includes surgery, chemotherapy, and radiotherapy.

The term ENE has evolved from extracapsular extension, which was defined as extension of tumor beyond the lymph node capsule into the surrounding tissues. However, tumor can also extend beyond the lymph node parenchyma at the hilum where there is no capsule. Thus, the term ENE is now considered appropriate terminology.

Histopathology (microscopic examination of tissue) was the gold standard for determining ENE. However, iENE has been identified as an independent risk factor for overall survival of patients with head and neck cancer. Therefore, it has been incorporated into AJCC version 9 for nasopharyngeal carcinoma, HPV-OPSCC, and salivary gland cancers.

Several grading systems have been proposed in the literature. All recognize that imaging findings are on a spectrum ranging from infiltration of surrounding fat to involvement of adjacent structures.

In July 2024, a Delphi consensus recommendation by Henson et al. was released. This consisted of an international consortium of 21 national head and neck oncology groups. The goal was to assist in identifying and standardizing reporting of iENE.

Recent biopsy which may result in perinodal fat stranding and capsule irregularity was identified as a potential pitfall for determining iENE. The committee suggested the following pertinent findings to comment on in the radiology report:

1. Indistinct or irregular nodal margins
2. Extension into perinodal fat
3. Conglomerate, matted, and coalescent nodes (clear invasion through adjoining nodes)
4. Extension into adjacent structures (muscle, cutaneous soft tissue, glands, or neurovascular bundle)

Grading Systems for Extranodal Extension

The Delphi consensus group proposed a four-tier classification system, Grades 0 to 3:

• Grade 0: Absence of iENE
• Grade 1: Irregular, ill-defined nodal margins or extension into perinodal fat
• Grade 2: Tumor extension beyond the nodal margin of two or more adjoining nodes, thus appearing as a conglomerate
• Grade 3: Clear extension into surrounding structures

A size greater than 3 cm carries a higher risk for ENE. Capsular thickening and necrotic or cystic changes are not recommended as criteria for diagnosing iENE.

More recently, a joint task force provided radiologists with a structured framework for identifying iENE. The task force came from the Asian-Oceanian Society of Neuroradiology and Head & Neck Radiology (AOSHNR). The task force also came from the American Society of Head and Neck Radiology (ASHNR). The task force also came from the European Society of Head & Neck Radiology (ESHNR).

This task force stratifies iENE into four categories:

• No iENE
• Perinodal fat invasion
• Coalescent nodes
• Adjacent structure invasion

The task force limits grading to unequivocal radiologic findings. To minimize overcalling, it introduces detailed, structure-specific criteria. For example, loss of fat planes with adjacent muscle does not constitute muscle invasion. Arterial involvement requires near-circumferential encasement. Venous involvement requires tumor thrombus.

This classification system is offered in the AJCC Version 9 for HPV-OPSCC. However, grading level has not been integrated into the N category.

How Extranodal Extension Affects Cancer Staging

The presence of iENE has direct implications for cancer staging and treatment decisions.

For nasopharyngeal carcinoma, iENE designates N3 category disease without the need for pathologic confirmation.

In AJCC Version 9 for HPV-OPSCC, unequivocal iENE now increases the clinical N category by one level.

For salivary gland tumors, unequivocal iENE is N2 category disease.

These updates reflect the importance of imaging in staging and the prognostic significance of iENE. Extranodal extension is associated with worse outcomes, thus warranting intensified treatment.

Lymphoproliferative Disorders: A Special Challenge

Lymphoproliferative diseases (LPD) require special consideration with respect to nodal reporting and measurements.

Lymphocytes are made in bone marrow and are found in blood and lymph tissue throughout the body. They play an integral role in immunity and have two main subtypes:

• B-cells: Responsible for humoral immunity (antibody production)
• T-cells: Responsible for cell-mediated immunity

LPD refers to the overproduction of lymphocytes, often occurring in immunocompromised patients. LPD may be secondary to an immunologic disorder or other underlying condition.

For lymphoproliferative disorders, diffuse lymphadenopathy (widespread lymph node enlargement) presents a challenge in reporting the size and number of lymph nodes. The authors note that this area requires special attention in radiology reporting.

Limitations of Current Imaging Approaches

Recent investigations evaluating iENE demonstrate important limitations in diagnostic performance and reproducibility.

Established radiographic criteria for iENE on CT demonstrate limited interobserver agreement, even among expert neuroradiologists and across multidisciplinary clinicians. This raises concerns regarding reliability in routine clinical decision-making.

Although MRI may offer relatively higher specificity compared with CT, overall diagnostic consistency remains suboptimal.

Together, these findings underscore the need for stronger standardized interpretation frameworks. They also highlight the potential need for adjunctive diagnostic tools to improve preoperative ENE assessment and risk stratification.

The authors emphasize that discussion with multidisciplinary tumor board stakeholders is essential for accurate interpretation and treatment planning.

Clinical Implications for Patients

This review has several important implications for patients with head and neck cancer:

• Accurate staging depends on detailed imaging. The size, location, and characteristics of lymph nodes directly affect cancer stage, which in turn affects treatment options.
• Size alone is not enough. Up to 50% of metastatic nodes measure less than 0.5 cm. Doctors must look at shape, texture, and metabolic activity, not just size.
• PET imaging adds critical information. Some lymph nodes appear normal on CT or MRI but show abnormal metabolic activity on PET. This can change staging and treatment.
• Extranodal extension changes everything. When cancer breaks through the lymph node capsule, it increases the cancer stage and may require more intensive treatment.
• Post-treatment changes can mimic cancer. After surgery or radiation, lymph nodes may enlarge due to altered drainage rather than recurrent cancer. PET imaging helps distinguish between these possibilities.
• Cystic lymph nodes in adults should raise concern. A cystic lymph node at level II should be considered metastasis until proven otherwise, not dismissed as a benign cyst.

Recommendations and Practical Approach

The authors provide a systematic, reproducible checklist approach for lymph node reporting in the head and neck. This approach aims to reduce inter-reader variability and produce a useful radiologic report for the multidisciplinary team.

Key recommendations include:

1. Report long-axis measurements to ensure concordance with AJCC staging.
2. Describe morphologic features including shape, fatty hilum presence, and internal characteristics.
3. Comment on necrosis and cystic changes as these have the highest specificity for metastatic disease.
4. Correlate with PET imaging when available to identify metabolically active nodes that appear normal on anatomic imaging.
5. Specifically address extranodal extension using standardized terminology and grading when possible.
6. Document the presence of conglomerate or matted nodes as these suggest extranodal extension.
7. Note extension into adjacent structures including muscle, skin, glands, or neurovascular bundles.
8. Consider post-treatment changes when interpreting imaging after surgery or radiation.

For patients, this means that their radiology report should contain specific information about lymph node size, shape, and characteristics. The report should also address whether there are signs of extranodal extension. This information helps the cancer care team determine the most appropriate treatment approach.

The authors conclude that accurate characterization and reporting of cervical lymph nodes is critical when evaluating head and neck malignancies. Findings directly impact staging, treatment planning, and prognosis. Knowledge of lymphatic drainage patterns predicts nodal spread of disease and may help in identifying the primary malignancy.

Careful attention to morphologic changes improves diagnostic accuracy beyond size criteria alone. FDG-PET imaging serves as a valuable complementary tool when available. Identifying radiologic features of extranodal extension impacts AJCC staging and subsequently, treatment course.

Frequently Asked Questions

Why does lymph node evaluation matter in head and neck cancer?

Lymph nodes are often the first place head and neck cancer spreads. Accurate identification and characterization of lymph nodes is essential for cancer staging, prognosis, and treatment planning. Mischaracterizing a lymph node can lead to incorrect diagnoses and suboptimal treatment, so precise imaging evaluation and standardized reporting are needed across all medical centers.

Is lymph node size alone enough to tell if cancer has spread?

No. Size alone is unreliable. Up to 50% of metastatic nodes measure less than 0.5 cm, so small nodes can still contain cancer. Doctors must also look at shape, texture, loss of the fatty hilum, necrosis, cystic changes, and metabolic activity on PET imaging, not just size, to distinguish benign from malignant nodes.

What does extranodal extension mean and why does it matter?

Extranodal extension (ENE) means cancer has broken through the lymph node capsule into surrounding tissues. It is a negative prognostic factor associated with high risk for disease progression and metastasis. When detected on imaging, it can increase the cancer stage by one level and may require more intensive treatment, directly affecting staging and treatment decisions.

How does PET imaging help if CT or MRI looks normal?

PET imaging adds metabolic information that CT and MRI cannot show. Some lymph nodes appear normal on CT or MRI but show abnormal metabolic activity on PET. Correlating anatomic findings with PET allows improved identification of metastatic nodes that maintain normal size, which may otherwise be missed, and can change staging and treatment.

After surgery or radiation, could an enlarged lymph node be something other than cancer?

Yes. Treatment can disrupt normal lymphatic flow, causing lymphedema and enlarged lymph nodes that may be transient or persist. An enlarging node may appear at an atypical location. Doctors must differentiate normal enlargement due to altered drainage from recurrent cancer. PET imaging helps distinguish these, and biopsy may be necessary for definitive characterization.

What does it mean if a lymph node is described as cystic?

A cystic lymph node has a well-defined fluid-filled cavity, which may be a manifestation of necrosis. In an adult, a cystic lymph node at level II should be considered metastasis until proven otherwise, not dismissed as a benign branchial cleft cyst or abscess. Cystic and necrotic changes have the highest specificity for metastatic disease.

What should a radiology report about lymph nodes include?

A useful report should include long-axis measurements for AJCC staging, morphologic features such as shape and fatty hilum presence, and comments on necrosis and cystic changes. It should also address extranodal extension using standardized terminology, document conglomerate or matted nodes, and note extension into adjacent structures. This helps the cancer care team determine the most appropriate treatment.

When should a patient with head and neck cancer seek a second opinion on lymph node imaging and staging?

A second opinion is worth considering when a radiology report relies on node size alone, since up to 50% of metastatic nodes measure less than 0.5 cm, and when it does not address extranodal extension, which changes staging and treatment. Review is also reasonable when PET findings are not correlated with CT or MRI, when a cystic level II node is dismissed as benign, or when post-treatment enlargement is assumed to be recurrence. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original Article Title: Malignant lymph nodes of the head and neck: imaging pearls, pitfalls, and practical approach to reporting in the era of extranodal extension.

License: CC BY-NC-ND (open access)

Authors: Brahmbhatt PM, Bentley E, Edgar MA, Rhyner PA, Bhatt AA.

Affiliation: Department of Radiology and Department of Pathology, Mayo Clinic, Jacksonville, Florida, USA

Journal: Cancer Imaging (2026) 26:90

DOI: https://doi.org/10.1186/s40644-026-01049-1

Article Type: Review, Open Access

Clinical Trial Number: Not applicable

This patient-friendly article is based on peer-reviewed research. The original article was published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.